A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase

被引:2
作者
Qiu, Simei [1 ,2 ]
Liu, Yunfeng [1 ]
Li, Quhuan [1 ,2 ,3 ]
机构
[1] South China Univ Technol, Inst Biomech, Sch Biosci & Bioengn, Guangzhou, Peoples R China
[2] South China Univ Technol, Guangdong Prov Engn & Technol Res Ctr Biopharmace, Guangzhou, Peoples R China
[3] South China Univ Technol, Sch Biosci & Bioengn, Guangzhou 510006, Guangdong, Peoples R China
来源
ROYAL SOCIETY OPEN SCIENCE | 2021年 / 8卷 / 08期
基金
中国国家自然科学基金;
关键词
activation mechanism; Bruton's tyrosine kinase; T474M mutation; X-LINKED AGAMMAGLOBULINEMIA; IRREVERSIBLE INHIBITORS; TARGETING BTK; IBRUTINIB; DISCOVERY; MUTATION; PATHWAY; BINDING; CANCER; CELLS;
D O I
10.1098/rsos.210066
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Bruton's tyrosine kinase (BTK) plays a vital role in mature B-cell proliferation, development and function. Its inhibitors have gradually been applied for the treatment of many B-cell malignancies. However, because of treatment-associated drug resistance or low efficacy, it is urgent to develop new inhibitors and/or improve the efficacy of current inhibitors, where finding the intrinsic activation mechanism becomes the key to solve this problem. Here, we used BTK T474M mutation as a resistance model for inhibitors to study the mechanism of BTK activation and drug resistance by free molecular dynamics simulations. The results showed that the increase of kinase activity of T474M mutation is coming from the conformation change of the activation ring and ATP binding sites located in BTK N-terminus region. Specifically, the Thr(474) mutation changed the structure of A-loop and stabilized the binding site of ATP, thus promoting the catalytic ability in the kinase domain. This localized dynamics-driven activation mechanism and resistance mechanism of BTK may provide new ideas for drug development in B-cell malignancies.
引用
收藏
页数:11
相关论文
共 42 条
  • [11] Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
    Guo, Yunhang
    Liu, Ye
    Hu, Nan
    Yu, Desheng
    Zhou, Changyou
    Shi, Gongyin
    Zhang, Bo
    Wei, Min
    Liu, Junhua
    Luo, Lusong
    Tang, Zhiyu
    Song, Huipeng
    Guo, Yin
    Liu, Xuesong
    Su, Dan
    Zhang, Shuo
    Song, Xiaomin
    Zhou, Xing
    Hong, Yuan
    Chen, Shuaishuai
    Cheng, Zhenzhen
    Young, Steve
    Wei, Qiang
    Wang, Haisheng
    Wang, Qiuwen
    Lv, Lei
    Wang, Fan
    Xu, Haipeng
    Sun, Hanzi
    Xing, Haimei
    Li, Na
    Zhang, Wei
    Wang, Zhongbo
    Liu, Guodong
    Sun, Zhijian
    Zhou, Dongping
    Li, Wei
    Liu, Libin
    Wang, Lai
    Wang, Zhiwei
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (17) : 7923 - 7940
  • [12] Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors
    Hantschel, Oliver
    [J]. ACS CHEMICAL BIOLOGY, 2015, 10 (01) : 234 - 245
  • [13] Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA):: 47 unique mutations without correlation to clinical course
    Holinski-Feder, E
    Weiss, M
    Brandau, O
    Jedele, KB
    Nore, B
    Bäckesjö, CM
    Vihinen, M
    Hubbard, SR
    Belohradsky, BH
    Smith, CIE
    Meindl, A
    [J]. PEDIATRICS, 1998, 101 (02) : 276 - 284
  • [14] VMD: Visual molecular dynamics
    Humphrey, W
    Dalke, A
    Schulten, K
    [J]. JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 1996, 14 (01) : 33 - 38
  • [15] Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
    Johnson, Adam R.
    Kohli, Pawan Bir
    Katewa, Arna
    Gogol, Emily
    Belmont, Lisa D.
    Choy, Regina
    Penuel, Elicia
    Burton, Luciana
    Eigenbrot, Charles
    Yu, Christine
    Ortwine, Daniel F.
    Bowman, Krista
    Franke, Yvonne
    Tam, Christine
    Estevez, Alberto
    Mortara, Kyle
    Wu, Jiansheng
    Li, Hong
    Lin, May
    Bergeron, Philippe
    Crawford, James J.
    Young, Wendy B.
    [J]. ACS CHEMICAL BIOLOGY, 2016, 11 (10) : 2897 - 2907
  • [16] Achieving a Graded Immune Response: BTK Adopts a Range of Active/Inactive Conformations Dictated by Multiple Interdomain Contacts
    Joseph, Raji E.
    Wales, Thomas E.
    Fulton, D. Bruce
    Engen, John R.
    Andreotti, Amy H.
    [J]. STRUCTURE, 2017, 25 (10) : 1481 - +
  • [17] Activation Loop Dynamics Determine the Different Catalytic Efficiencies of B Cell- and T Cell-Specific Tec Kinases
    Joseph, Raji E.
    Kleino, Iivari
    Wales, Thomas E.
    Xie, Qian
    Fulton, D. Bruce
    Engen, John R.
    Berg, Leslie J.
    Andreotti, Amy H.
    [J]. SCIENCE SIGNALING, 2013, 6 (290)
  • [18] Identification of an Allosteric Signaling Network within Tec Family Kinases
    Joseph, Raji E.
    Xie, Qian
    Andreotti, Amy H.
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2010, 403 (02) : 231 - 242
  • [19] BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers
    Lavitrano, Marialuisa
    Ianzano, Leonarda
    Bonomo, Sara
    Cialdella, Annamaria
    Cerrito, Maria Grazia
    Pisano, Fabio
    Missaglia, Carola
    Giovannoni, Roberto
    Romano, Gabriele
    McLean, Chelsea M.
    Voest, Emile E.
    D'Amato, Filomena
    Noli, Barbara
    Ferri, Gian Luca
    Agostini, Marco
    Pucciarelli, Salvatore
    Helin, Kristian
    Leone, Biagio E.
    Canzonieri, Vincenzo
    Grassilli, Emanuela
    [J]. JOURNAL OF PATHOLOGY, 2020, 250 (02) : 134 - 147
  • [20] Insight into resistance mechanisms of AZD4547 and E3810 to FGFR1 gatekeeper mutation via theoretical study
    Liang, Donglou
    Chen, Qiaowan
    Guo, Yujin
    Zhang, Ting
    Guo, Wentao
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 451 - 461